Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Anastomotic Leak 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Neomycin × Clear all
NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02682485 2023-04-26

SES-DTA

University of Chicago

Phase 2 Withdrawn
Gastrointestinal

Rectal Neoplasms, Anastomotic Leak

Data powered by HemOnc (CC BY 4.0) Colophon âš¡